Skip to Main Contents
Integrated search
Korea lays out blueprint for nurturing global biopharma hub
  • Registration date2024-04-02
  • Attached file

Trade, Industry and Energy Minister Dukgeun Ahn held a meeting on biopharma manufacturing competitiveness at the Pangyo Technovalley's Startup Campus on April 1 to lead discussions on biomanufacturing development and future strategies with representatives of major producers of bio materials, parts and equipment (MPE) like Hanhwa and Amicogen, and bio companies like Samsung Biologics and Celltrion.


MOTIE is aiming to secure Korea’s supergap in advanced biomanufacturing by pouring KRW 2.1 trillion from 2024-2030 into R&D support for global market penetration and the establishment of a bio MPE ecosystem and industrial base to assist 17.7 trillion won worth of private investment by 2030. This is in line with the goal of nurturing five contract development and manufacturing organizations (CDMOs) and five global bio MPE companies by 2030. By 2030, MOTIE intends to produce 15 trillion won worth of bio pharmaceuticals and achieve USD 10 billion in their export.


The ministry will also push a prefeasibility study for the Korean version of BioMADE, a project for advancing the high-tech bio production process. In order to advance the production process and accelerate commercialization in tandem with the public bio foundry project to be launched next year, MOTIE will collaborate with the U.S.’ Advanced Mammalian Biomanufacturing Innovation Center (AMBIC) in establishing an innovative bio manufacturing platform.


Prior to the meeting, Korea’s Bio MPE Solidarity Cooperation Consultative Group entered a memorandum of understanding (MOU) with major bio companies like Samsung Biologics, Celltrion, and Samsung Bioepis, as well as research and education institutions like the Korea Research Institute of Bioscience and Biotechnology (KRIBB), K-NIBRT and Osong Medical Innovation Foundation to strengthen support for bio MPE firms’ demonstration projects. Companies and institutions participating in this MOU will be engaging in the establishment of a bio MPE testbed project through the Bio MPE Solidarity Cooperation Consultative Group for securing MPE products’ track record beginning this year.